[{"bbox": [90, 98, 370, 134], "category": "Page-header", "text": "Q-Line Biotech Limited"}, {"bbox": [90, 171, 1563, 300], "category": "Text", "text": "may result in termination of our contracts with our customers, which could have an adverse effect on our business, reputation and financial results. Further, we may also be open to public liability from the end consumer for defects in the quality of perishable products we store and transport. Accordingly, any breakdown of our machinery or equipment may have a significant effect on our business, reputation, financial results and growth."}, {"bbox": [90, 329, 879, 364], "category": "Section-header", "text": "**32. We are subject to risks arising from exchange rate fluctuations.**"}, {"bbox": [90, 393, 1563, 619], "category": "Text", "text": "Although our reporting currency is Indian Rupees, we transact a portion of our business in several other currencies, primarily in U.S. dollars and Euros. For the Financial Years 2023, 2024 and 2025 our purchases from outside India amounted to ₹7169.71 Lakhs, ₹11707.65 Lakhs, and ₹8680.93 Lakhs, respectively, representing 73.74%, 74.81%, and 60.41%, respectively, of our total purchases on standalone basis. Additionally, we are also required to pay certain expenses in foreign currency such as Royalty for manufacturing our machines and reagents on account of technical tie up with the European company, as a result, incur such costs in currencies other than the Indian Rupee. Also, we export small portion of our revenue in the foreign currency. Below table represents the amount of royalty payment made, export sales in the foreign currency on standalone basis:-"}, {"bbox": [1425, 617, 1560, 648], "category": "Text", "text": "(₹ in lakhs)"}, {"bbox": [90, 645, 1561, 751], "category": "Table", "text": "<table><thead><tr><td>Particulars</td><td>March 25</td><td>March 24</td><td>March 23</td></tr></thead><tbody><tr><td>Royalty exp</td><td>1586.97</td><td>502.71</td><td>17.79</td></tr><tr><td>Export sales</td><td>35.37</td><td>22.24</td><td>11.47</td></tr></tbody></table>"}, {"bbox": [90, 782, 1563, 1009], "category": "Text", "text": "Also, we have capitalised payment made in foreign currency for technical tie up. Further, we may be required to incur non-Rupee indebtedness in the form of external commercial borrowings and other foreign currency denominated borrowings, which may create foreign currency exposure in respect of our cash flows and ability to service such debt. As of March 31, 2025, we are not having any foreign currency loans from banks. We are, therefore, exposed to exchange rate fluctuations due to the revenue that we receive, the raw materials that we purchase and our royalty payment among others that are denominated in currencies other than the Indian Rupee. In addition, the policies of the RBI may also change from time to time, which may limit our ability to effectively hedge our foreign currency exposures, if any, and may have an adverse effect on our business, financial condition, cash flows and results of operations."}, {"bbox": [90, 1038, 1563, 1136], "category": "Section-header", "text": "**33. Our products may not provide proper results if the reagent is not as per the quality standard or the machinery is not functioning properly or for any other reasons, which may affect adversely our business operations, cash flow and profitability.**"}, {"bbox": [90, 1165, 1563, 1425], "category": "Text", "text": "Although we are taking clinical trial and testing of our reagents however there may be chances of improper results of test as result of factors which may not be in our control. These factors become known when the product is actually launched in the market and tested on the samples taken from the human body, unusual but severe side effects in isolated cases, defective products not detected by our quality management system or misuse of our products by consumers. Although we have taken various measures relating to quality and safety control, if any of the foregoing were to occur, we may face a number of consequences, including, death or injury, withdrawal of specific or complete regulatory approvals, cancellation of licence, inventory loss on product recall, loss of reputations, closure of business operations on temporary or permanent basis, restriction on operating in particular region, lawsuits or claims against the company/directors/promotors."}, {"bbox": [90, 1453, 1563, 1582], "category": "Text", "text": "In certain jurisdictions, the quantum of damages awarded in cases of product liability may be punitive in nature. Product liability claims, regardless of their merits or the ultimate success of the defense against them, are costly, could damage our reputation and affect our operations. As a result of these consequences, our business, financial condition, cash flows and results of operations may be adversely affected."}, {"bbox": [90, 1614, 1563, 1680], "category": "Section-header", "text": "**34. Any actual or perceived cybersecurity, data or privacy breach could interrupt our operations and adversely affect our reputation, brand, business, financial condition and results of operations.**"}, {"bbox": [90, 1709, 1563, 2031], "category": "Text", "text": "Our platform and back-end infrastructure may be vulnerable to cyberattacks and security breaches including social engineering, denial of service, credential stuffing, ransomware and other malware, employee error and malfeasance and other sources of disruption, and third parties may be able to access data. Employee error, malfeasance, or other errors in the storage, use or transmission of any of these types of data could result in an actual or perceived privacy or security breach or other security incident. Although we have policies, system controls and checks restricting the access to the data we store, there is a risk that these policies may not be effective in all cases. Any actual or perceived breach or similar incident could interrupt our operations; harm our reputation, brand and competitive position; result in our platform being unavailable; result in loss or unavailability of data; or result in a fraudulent transfer of funds; significant regulatory investigations, proceedings and financial exposure. Any such incidents or any perception that our security measures are inadequate could lead to loss of Customer. However, we have not faced any such situation but this does give us guarantee of non-occurrence of these events in future."}, {"bbox": [90, 2060, 1563, 2128], "category": "Section-header", "text": "**35. The “Q-line” brand, is critical to our ability to acquire new users and grow our business. If we are not able to maintain our brand or reputation our operations could materially and adversely affect user acceptance of our platform and our operations.**"}]